Make an enquiry
Refer a patient
Pay my bill
0808 304 2332

We noticed you are on our UK page. Want to switch regions? Choose from the options:

AU
ES
GenesisCare - logo
Patients
Cancer care
Exploring cancer care
Bladder cancer
Head & neck cancer
Lung cancer
Prostate cancer
Bowel cancer
Kidney cancer
Non-Hodgkin's lymphoma
Skin cancer
Breast cancer
Leukaemia
Ovarian cancer
All cancers we treat
Diagnosis
Cancer diagnosis
Breast diagnostics
Prostate diagnostics
Diagnostic clinics
Pathology tests
Blood tests
Bone marrow test
Flexible cystoscopy
Imaging scans
CT scanning
MRI scanning
PET-CT scan
Prostate mpMRI scan
Treatments
Cancer treatments
Breast cancer
Prostate cancer
Pancreatic cancer
Lung cancer
Palliative
Radiotherapy
SABR
MRIdian
EBRT
IMRT
VMAT
Chemotherapy & SACTs
Hormone therapy
Targeted therapies
Immunotherapy
Theranostics
177Lutetium
Radium-223
Patient support
Patient resources
Glossary of medical terms
Helpful organisations
Going private
Paying for treatment
LGBTIQ+ cancer care
Cancer wellbeing blog
Breast cancer early signs
Checking for prostate cancer
Having cancer without knowing
Patient stories
Marco's journey
Diana's journey
Liz's journey
Integrative cancer care
Exercise medicine
Wellbeing services
Sleep support
About us
Who we are
Our Board
Contact us
Why choose GenesisCare
Governance and safety
About clinical trials
Current clinical trials
Careers
Our benefits
News
Our campaigns
Healthcare professionals
Oncology
Treatments
Radiotherapy
Chemotherapy & SACT's
Theranostics
Diagnostics
Diagnostic clinics
Diagnostic tests and scans
Integrative cancer care
Penny Brohn
Exercise medicine
Palliative treatments
Specialties
Breast oncology
Head & neck oncology
Prostate oncology
Research
Clinical trials
Clinical Publications
About us
Practising privileges
Clinician leads & governance
Access our services
Innovations blog
Resources
Breast Illustrations
Case Studies
MRIdian case studies
Head and neck case study
Diagnostics case study
Blood cancer case study
Governance
Find a centre
Find a doctor
GenesisCare - logo
0808 304 2332
Make an enquiry
Refer a patient
Pay my bill

We noticed you are on our UK page. Want to switch regions? Choose from the options:

AU
ES
Find a centre
Find a doctor
Patients
Cancer care
Exploring cancer care
Bladder cancer
Head & neck cancer
Lung cancer
Prostate cancer
Bowel cancer
Kidney cancer
Non-Hodgkin's lymphoma
Skin cancer
Breast cancer
Leukaemia
Ovarian cancer
All cancers we treat
Diagnosis
Cancer diagnosis
Breast diagnostics
Prostate diagnostics
Diagnostic clinics
Pathology tests
Blood tests
Bone marrow test
Flexible cystoscopy
Imaging scans
CT scanning
MRI scanning
PET-CT scan
Prostate mpMRI scan
Treatments
Cancer treatments
Breast cancer
Prostate cancer
Pancreatic cancer
Lung cancer
Palliative
Radiotherapy
SABR
MRIdian
EBRT
IMRT
VMAT
Chemotherapy & SACTs
Hormone therapy
Targeted therapies
Immunotherapy
Theranostics
177Lutetium
Radium-223
Patient support
Patient resources
Glossary of medical terms
Helpful organisations
Going private
Paying for treatment
LGBTIQ+ cancer care
Cancer wellbeing blog
Breast cancer early signs
Checking for prostate cancer
Having cancer without knowing
Patient stories
Marco's journey
Diana's journey
Liz's journey
Integrative cancer care
Exercise medicine
Wellbeing services
Sleep support
About us
Who we are
Our Board
Contact us
Why choose GenesisCare
Governance and safety
About clinical trials
Current clinical trials
Careers
Our benefits
News
Our campaigns
Healthcare professionals
Oncology
Treatments
Radiotherapy
Chemotherapy & SACT's
Theranostics
Diagnostics
Diagnostic clinics
Diagnostic tests and scans
Integrative cancer care
Penny Brohn
Exercise medicine
Palliative treatments
Specialties
Breast oncology
Head & neck oncology
Prostate oncology
Research
Clinical trials
Clinical Publications
About us
Practising privileges
Clinician leads & governance
Access our services
Innovations blog
Resources
Breast Illustrations
Case Studies
MRIdian case studies
Head and neck case study
Diagnostics case study
Blood cancer case study
Governance
Make an enquiry
Refer a patient
Pay my bill
0808 304 2332
  • Healthcare Professionals
  • Resources
  • Case studies
  • Gastric MALT Lymphoma

Gastric MALT Lymphoma

A case study of MR-guided adaptive radiotherapy for gastric MALT lymphoma.

Shot of a happy senior man using a digital tablet while spending some time with his adult son at home

Case study

Enquire

MR-guided adaptive radiotherapy for gastric MALT lymphoma

Dr Veni Ezhil

Dr Veni Ezhil is a Consultant Clinical Oncologist in Guildford, Oxford, and London. She specialises in respiratory motion management and advanced technical radiotherapy. She is currently the SABR lead for the treatment of oligometastases at Royal Surrey County Hospital.

image

Case presentation

In January 2022, a 39-year-old male presented with a one year history of nausea, abdominal discomfort, and weight loss. The patient was referred to a gastroenterologist, who performed an endoscopy and biopsied an area of thickened stomach wall which confirmed the diagnosis of marginal zone lymphoma. Sample was negative for H. pylori.

Patient was referred to a haematologist for the treatment of gastric MALT lymphoma.

A staging PET-CT scan confirmed the stomach and a small left gastric lymph node to be the only sites involved staging him IAE. Examination of the bone marrow was negative.

The patient was otherwise fit and fully active with a PS-0.

image

Fig 1: PET-CT showing uptake in the stomach

Patient was treated with four cycles of Rituximab to reduce the risk of distant relapse and was referred for radiotherapy to the stomach.

Challenges of presentation and choice of treatment

Radiotherapy to the stomach is challenging due to the daily changes in the shape and volume of the stomach over the course of treatment and movement of the stomach with respiration. It’s also difficult to visualise the stomach on daily non-contrast CT images on the treatment machine to guide accurate delivery of radiotherapy.

A large margin (2-3 cm) is typically applied to the stomach to overcome these challenges, resulting in a large volume of surrounding normal structures included in the radiation volume leading to increased toxicity.

MR-guided adaptive radiotherapy for gastric MALT lymphoma overcomes all the three challenges that cause concern with gastric radiotherapy, allowing for an ultra-accurate treatment delivery with reduced toxicity. The aim of this treatment method is to eradicate the disease in the stomach and achieve local control in early-stage lymphoma localised to the stomach.

Alternative treatment would have been to treat on a conventional linac using a respiratory correlated CT scan for simulation to account for motion associated with breathing and use a 2-3 cm margin to account for the daily changes in the shape and size of the stomach.

Treatment

The patient received treatment at GenesisCare, London Cromwell Hospital on the MRIdian MR linac. Treatment involved ISRT (involved site radiotherapy) to the stomach and the involved node delivering 24Gy in 12#, five days a week. An 8 mm PTV margin was given to the target to account for changes during treatment. Doses to the heart, kidneys and spleen were aimed to be kept as low as possible. 

image

Fig 2: Planning MRI with the target and nearby organs at risk

The patient’s treatment was delivered in inspiration breath hold, tracking the stomach in real-time and delivering radiation only when the stomach was within the defined boundary. This improved the accuracy of delivery, allowing for opportunities to stop and amend where required.

On the first day of treatment, the shape and volume of the stomach was found to be very different from the planning scan. Complete recontouring was carried out to reflect the shape and volume of the stomach on the day. Surrounding organs at risk (OARs), heart, kidneys, spleen, and spinal cord, were also amended as required. The treatment plan was re-optimised to get the best dose to the target and as low dose as possible to the surrounding organs. This step overcomes the challenge of the daily change in the anatomy of the stomach.

On the second day of treatment, a gas bubble appeared during treatment which displaced the stomach out of the boundary. We were able to see this, stop treatment and recontour and plan before restarting treatment.

The target and nearby OARs were recontoured daily for all 12 fractions of treatment to accommodate the change in anatomy and the treatment plan was re-optimised to the new contours. As the size and shape of the stomach changed significantly every day, it needed complete recontouring rather than editing. The total time on bed for each session was 60 minutes.

image

Fig 3: Change in the shape and volume of stomach at different fractions

Side effects and management

The patient experienced nausea during radiotherapy and was given prophylactic anti-sickness medications to help control this during sessions. He did report tiredness during treatment but otherwise tolerated radiotherapy well without any significant toxicity. His weight remained stable during his treatment.

Results and follow-up

The patient was reviewed at four weeks to rule out any toxicity from radiotherapy and was discharged for follow up with the haematologist.

The patient had an endoscopy three months after completion of radiotherapy to assess response which showed no evidence of lymphoma.

Discussion

This was the first case of gastric MALT lymphoma treated at GenesisCare using MR-Guided adaptive radiotherapy. We were able to accommodate the daily changes in anatomy and maximise local control and minimise toxicity.

The time on table was longer than conventional radiotherapy due to the time taken for adapting the contours and plan. With upcoming developments on MRIdian and further clinical experience we believe the time on bed can be reduced to make it easier for the patients.

UK Genesis Logo

GenesisCare UK

Careers
Gender pay gap reports
UK tax strategy

Website policies

Privacy Information for Data Subjects
Patient terms and conditions
Modern slavery act transparency
Section 172 Statement by Directors
Cookie Preferences

Contact us

Make an Enquiry
Concerns, Comments, Complaints? (NHS patients)
Concerns, Comments, Complaints? (Private patients)

Media & Social

News Room - What's been happening
Facebook
X
Linkedin
Youtube
Vimeo

Copyright © 2024 GenesisCare. All Rights Reserved.

Genesis Cancer Care UK Limited (05796994) is incorporated in England & Wales and has its registered office at: Wilson House, Waterberry Drive, Waterlooville, Hampshire, PO7 7XX